Erratum to: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas (Journal of Neuro-Oncology DOI: 10.1007/s11060-010-0190-0);A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas

Journal of Neuro-Oncology

Volumn 100, Issue 2, 2010, Pages 261-268

  Peereboom, David M ^a   Supko, Jeffrey G ^b   Carson, Kathryn A ^c   Batchelor, Tracy ^b   Phuphanich, Surasak ^d   Lesser, Glenn ^e   Mikkelson, Tom ^f   Fisher, Joy ^g   Desideri, Serena ^g   He, Xiaoying ^b   Grossman, Stuart A ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Ixabepilone; Phase II; Recurrent gliomas

Indexed keywords

EPOTHILONE A; IXABEPILONE; NITROSOUREA;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HEMATOLOGIC DISEASE; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; VOMITING;

EID: 79952188360     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0234-5     Document Type: Erratum

References (39)

1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. Cancer J Clin 49:8-31
2. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H (1996) Epothilons A and B: antifungal and cytotoxic compounds from sorangium cellulosum (myxobacteria) production, physicochemical and biological properties. J Antibiot 49:560-563 (Pubitemid 26235665)
3. Bollag DM, McQueney PA, Zhu J et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333
4. Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (taxol(R)). J Biol Chem 272:2534-2541 (Pubitemid 27058547)
5. Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437 (Pubitemid 32708699)
6. Muhlradt PF, Sasse F (1997) Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity. Cancer Res 57:3344-3346 (Pubitemid 27355471)
7. Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295-2305 (Pubitemid 46954658)
8. Chamberlain MC, Kormanik P (1999) Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol 43:71-78 (Pubitemid 29351980)
9. Chang SM, Kuhn JG, Robins HI et al (2001) A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American brain tumor consortium report. Cancer 91:417-422 (Pubitemid 32099244)
10. Prados MD, Schold SC, Spence AM et al (1996) Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14:2316-2321
11. Peterson JK, Tucker C, Favours E et al (2005) In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 11:6950-6958
12. Goel S, Cohen M, Cömezoglu SN et al (2008) The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 14:2701-2709
13. Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404-409 (Pubitemid 36793932)
14. Abraham J, Agrawal M, Bakke S et al (2003) Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21:1866-1873 (Pubitemid 46638601)
15. Aghajanian C, Burris HA III, Jones S et al (2007) Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 25:1082-1088 (Pubitemid 46596760)
16. Larkin JM, Kaye SB (2007) Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 18:28-34
17. Piantadosi S, Fisher JD, Grossman S (1998) Practical implementation of a modified continual reassessment method for dosefinding trials. Cancer Chemother Pharmacol 41:429-436 (Pubitemid 28140705)
18. Shah VP, Midha KK, Dighe S et al (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 16:249-255
19. Lacey LF, Keene ON, Pritchard JF, Bye A (1997) Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? J Biopharm Stat 7:171-178
20. Mizuta E, Tsubotani A (1985) Preparation of mean drug concentration - time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull 33:1620-1632
21. Beumer JH, Garner RC, Cohen MB et al (2007) Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs 25:327-334 (Pubitemid 46944849)
22. Zhou S, Yung Chan S, Cher Goh B et al (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304 (Pubitemid 40477790)
23. Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American academy of neurology. Neurology 54:1886-1893
24. Tanaka E (1999) Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 24:87-92
25. Chang SM, Kuhn J, Wen P et al (2004) Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22:427-435 (Pubitemid 39619819)
26. Cloughesy TF, Kuhn J, Robins HI et al (2005) Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American brain tumor consortium study. J Clin Oncol 23:6647-6656 (Pubitemid 46190259)
27. Fetell MR, Grossman SA, Fisher JD et al (1997) Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium. J Clin Oncol 15:3121-3128
28. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294-5304 (Pubitemid 46206983)
29. Gilbert MR, Supko JG, Batchelor T et al (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9:2940-2949 (Pubitemid 37006309)
30. Grossman SA, Hochberg F, Fisher J et al (1998) Increased 9- aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS consortium the new approaches to brain tumor therapy. Cancer Chemother Pharmacol 42:118-126 (Pubitemid 28267292)
31. Phuphanich S, Baker SD, Grossman SA et al (2005) Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol 7:177-182
32. Prados MD, Lamborn KR, Chang S et al (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8:67-78 (Pubitemid 43154453)
33. Reardon DA, Egorin MJ, Quinn JA et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368
34. Reardon DA, Quinn JA, Vredenburgh JJ et al (2006) Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 12:860-868 (Pubitemid 43259869)
35. Luo G, Cunningham M, Kim S et al (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804 (Pubitemid 34671092)
36. Raucy JL (2003) Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31:533-539
37. Faucette SR, Wang H, Hamilton GA et al (2004) Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32:348-358 (Pubitemid 38263894)
38. Mani S, McDaid H, Hamilton A et al (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289-1298 (Pubitemid 38365219)
39. Gadgeel SM, Wozniak A, Boinpally RR et al (2005) Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 11:6233-6239 (Pubitemid 41262953)